Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Inv. presentation
CC transcript
REGENERON PHARMACEUTICALS, INC. (REGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Regeneron Reports Second Quarter 2023 Financial and Operating Results"
02/03/2023 8-K Quarterly results
Docs: "Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results"
08/03/2022 8-K Quarterly results
Docs: "Regeneron Reports Second Quarter 2022 Financial and Operating Results"
05/04/2022 8-K Quarterly results
02/04/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Regeneron Reports Third Quarter 2021 Financial and Operating Results"
08/05/2021 8-K Quarterly results
Docs: "Regeneron Reports Second Quarter 2021 Financial and Operating Results"
05/06/2021 8-K Quarterly results
02/05/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Regeneron Reports Third Quarter 2020 Financial and Operating Results"
08/05/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
02/06/2020 8-K Quarterly results
Docs: "Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results"
11/05/2019 8-K Quarterly results
Docs: "Regeneron Reports Third Quarter 2019 Financial and Operating Results"
08/06/2019 8-K Quarterly results
Docs: "Regeneron Reports Second Quarter 2019 Financial and Operating Results"
05/07/2019 8-K Quarterly results
Docs: "Regeneron Reports First Quarter 2019 Financial and Operating Results"
02/06/2019 8-K Quarterly results
11/06/2018 8-K Quarterly results
Docs: "Regeneron Reports Third Quarter 2018 Financial and Operating Results"
08/02/2018 8-K Quarterly results
Docs: "Regeneron Reports Second Quarter 2018 Financial and Operating Results • Second quarter 2018 GAAP net income per diluted share increased by 44% to $4.82 versus second quarter 2017 and second quarter 2018 non-GAAP net income per diluted share increased 31% to $5.45 versus second quarter 2017 • Second quarter 2018 EYLEA ® Injection U.S. net sales increased 8% to $992 million versus second quarter 2017 and second quarter 2018 EYLEA global net sales increased 13% to $1.66 billion versus second quarter 2017 • Positive results reported from Phase 3 trial of Dupixent ® in adolescents with inadequately controlled moderate-to-severe atopic dermatitis Tarrytown, New York -- Regeneron Pharmaceuticals, Inc. today announced financial results for the second quarter of 2018 and provided a business update...."
05/03/2018 8-K Quarterly results
Docs: "Regeneron Reports First Quarter 2018 Financial and Operating Results"
02/08/2018 8-K Quarterly results
Docs: "Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results"
11/08/2017 8-K Quarterly results
Docs: "Regeneron Reports Third Quarter 2017 Financial and Operating Results"
08/03/2017 8-K Quarterly results
Docs: "Regeneron Reports Second Quarter 2017 Financial and Operating Results"
05/04/2017 8-K Form 8-K - Current report
02/09/2017 8-K Form 8-K - Current report
11/04/2016 8-K Quarterly results
Docs: "Regeneron Reports Third Quarter 2016 Financial and Operating Results • Third quarter 2016 EYLEA ® Injection U.S. net sales increased 16% to $854 million versus third quarter 2015 • Third quarter 2016 EYLEA global net sales increased 20% to $1.32 billion versus third quarter 2015 • Biologics License Application for Dupixent ® in atopic dermatitis accepted for priority review by FDA Tarrytown, New York -- Regeneron Pharmaceuticals, Inc. today announced financial results for the third quarter of 2016 and provided a business update."
08/04/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
02/09/2016 8-K Form 8-K - Current report
11/04/2015 8-K Form 8-K - Current report
08/04/2015 8-K Form 8-K - Current report
05/07/2015 8-K Form 8-K - Current report
02/10/2015 8-K Form 8-K - Current report
11/04/2014 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy